Prices for and Spending on Specialty Drugs in Medicare Part D and Medicaid

Congressional Budget Office

No 54964, Reports from Congressional Budget Office

Abstract: In recent years, the prices charged for specialty drugs have become a source of concern for many policymakers. Such drugs typically treat chronic, complex, or rare conditions, frequently have high prices, and may require special handling or patient monitoring. They accounted for a growing share of total net drug spending from 2010 to 2015 in both Medicare’s prescription drug benefit (Part D) and Medicaid. The net prices paid for specialty drugs are much higher in Medicare Part D than in Medicaid, and net spending on such drugs grew much faster in Medicare Part D than in Medicaid.

JEL-codes: I10 I11 I13 I18 (search for similar items in EconPapers)
Date: 2019-03-18
New Economics Papers: this item is included in nep-ias
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.cbo.gov/system/files/2019-03/54964-Specialty_Drugs.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cbo:report:54964

Access Statistics for this paper

More papers in Reports from Congressional Budget Office Contact information at EDIRC.
Bibliographic data for series maintained by ().